ClinConnect ClinConnect Logo
Search / Trial NCT06016946

Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study

Launched by FRIEDREICH'S ATAXIA RESEARCH ALLIANCE · Aug 23, 2023

Trial Information

Current as of July 23, 2025

Recruiting

Keywords

Rare Disease Neuro Degenerative Disease Ataxia Neurodegenerative Diseases Neurologic Manifestations Genetic Diseases, Inborn

ClinConnect Summary

The Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study is a research project aimed at understanding the progression of Friedreich ataxia, a genetic condition that affects movement and coordination. This study is taking place in multiple locations around the world and is designed to gather important information that can help in developing new treatments for this condition. Researchers are looking for participants of all ages, both males and females, who have been genetically confirmed to have Friedreich ataxia.

If you or a loved one is interested in participating, you’ll need to provide written consent, and if the participant is a minor, a parent or legal guardian will need to sign as well. Participants can expect to take part in various assessments over time, helping researchers learn more about how the disease affects individuals. This study is currently recruiting participants, but some people may not be eligible if they have other serious health issues or cannot provide consent. Your involvement could play a crucial role in advancing our understanding and treatment of Friedreich ataxia.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Both males and females of any age
  • 2. Individuals with Friedreich ataxia (FA): Participants that meet genetically confirmed diagnosis of Friedreich ataxia
  • 3. Written informed consent provided
  • 1. Informed consent must be obtained for all participants
  • 2. For underage participants, they and the parent/ legally authorized representative have to sign the informed consent form, child assent (if applicable)
  • 3. Persons who are not legally competent require the informed consent of their legally authorized representative
  • Exclusion Criteria:
  • 4. Unable or unwilling to provide informed consent
  • 5. Acute or ongoing medical or other conditions that would interfere with the conduct and assessments of the study
  • 6. For any reason in the opinion of the investigator, participant would be unlikely or unable to comply with study protocol requirements.

About Friedreich's Ataxia Research Alliance

The Friedreich's Ataxia Research Alliance (FARA) is a non-profit organization dedicated to advancing research and developing treatments for Friedreich's ataxia (FA), a rare genetic disorder that primarily affects movement and coordination. Established to foster collaboration among researchers, clinicians, and patient communities, FARA plays a pivotal role in funding innovative research initiatives, facilitating clinical trials, and promoting awareness of FA. Through strategic partnerships and advocacy, FARA aims to accelerate the discovery of effective therapies and improve the quality of life for individuals affected by this debilitating condition.

Locations

Philadelphia, Pennsylvania, United States

Memphis, Tennessee, United States

Denver, Colorado, United States

Toronto, Ontario, Canada

Auckland, , New Zealand

Milan, , Italy

Campinas, , Brazil

Innsbruck, , Austria

Aachen, , Germany

Bonn, , Germany

Tübingen, , Germany

Madrid, , Spain

Gainesville, Florida, United States

Tampa, Florida, United States

Atlanta, Georgia, United States

Columbus, Ohio, United States

Parkville, Victoria, Australia

Los Angeles, California, United States

Iowa City, Iowa, United States

Montréal, Quebec, Canada

Bruxelles, , Belgium

Praha, , Czechia

Paris, , France

Strasbourg, , France

Munich, , Germany

Athens, , Greece

Dublin, , Ireland

Roma, , Italy

Barcelona, , Spain

London, , United Kingdom

Paris, , France

New Delhi, Nct, India

Conegliano, , Italy

Bonn, , Germany

Montreal, Quebec, Canada

Nijmegen, , Netherlands

Memphis, Tennessee, United States

Patients applied

0 patients applied

Trial Officials

David Lynch, MD

Principal Investigator

Children's Hospital of Philadelphia

Jorg B Schulz, Prof

Principal Investigator

University Hospital, Aachen

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported